DHR vs MELI: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and MercadoLibre, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
VS
MercadoLibre, Inc. · Consumer Cyclical
$1,767.42
+41.4% upside to fair value
High Conviction
Grade A
QuantHub Verdict
MELI has more upside to fair value
(+41.4%).
DHR trades at a lower forward P/E
(33.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MELI |
| Current Price |
$174.04 |
$1,767.42 |
| Fair Value Estimate |
$197.01 |
$2,500.00 |
| Upside to Fair Value |
+13.2%
|
+41.4%
|
| Market Cap |
$123.2B |
$89.6B |
| Forward P/E |
33.4x
|
35.0x
|
| EV / EBITDA |
20.3x
|
18.5x
|
| Price / Sales |
5.0x
|
3.1x
|
| Price / FCF |
23.3x
|
8.9x
|
| Revenue Growth YoY |
+3.7%
|
+39.1%
|
| Gross Margin |
60.7%
|
44.5%
|
| Operating Margin |
21.0%
|
11.1%
|
| Return on Equity |
7.1%
|
33.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.3%
|
12.1%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
MercadoLibre is the dominant e-commerce and fintech ecosystem across Latin America, operating the largest marketplace and digital payments platform in a region with 670M+ people where e-commerce penetration is still under 15%. Revenue grew 39% to $28.9B in FY2025 with $10.8B in free cash flow — a 12% FCF yield at current prices. The company is trading at its 5-year P/S minimum (3.1x) and P/FCF mi…
Accumulation Zones
| Metric |
DHR |
MELI |
| Zone Low |
$147.76 |
$1,875.00 |
| Zone High |
$167.46 |
$2,125.00 |
| In Buy Zone? |
No
|
Yes
|